Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NateraMEX:NTRA 60 ROE % is -19.54% as of Mar. 2026. GuruFocus rates MEX:NTRA with a GF Score™ of 60/100 and a GF Value™ of MXN2,983.49 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Natera ranks worse than 67.5% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Natera's annualized net income for the quarter that ended in Mar. 2026 was MXN-6,138 Mil. Natera's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was MXN31,412 Mil. Therefore, Natera's annualized ROE % for the quarter that ended in Mar. 2026 was -19.54%.
The historical rank and industry rank for Natera's ROE % or its related term are showing as below:
MEX:NTRA'
s ROE % Range Over the Past 10 Years
Min: -445.14 Med: -74.61 Max: -14.32
Current: -15.66
During the past 13 years, Natera's highest ROE % was -14.32%. The lowest was -445.14%. And the median was -74.61%.
MEX:NTRA's ROE % is ranked worse than 67.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.32
vs MEX:NTRA: -15.66
Natera (MEX:NTRA) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Natera ROE % Related Terms
Natera ROE % Historical Data
* Premium members only.
The historical data trend for Natera's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Natera's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's ROE % distribution charts can be found below:
* The bar in red indicates where Natera's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Natera (MEX:NTRA) has a ROE % of -19.54% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Natera and its competitors. According to the industry distribution chart, Natera ranks #135 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 67.5%.
Is Natera's ROE % too high?
Natera's current ROE % is -19.54%. Based on the distribution chart, Natera ranks #135 out of 200 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Natera has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Natera's ROE % compare to WAT and A?
According to the Medical Diagnostics & Research industry distribution chart, Natera ranks #135 out of 200 companies for ROE %. This places Natera in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Natera and its competitors. Natera's current ROE % is -19.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natera stock overvalued right now?
Based on GuruFocus' analysis, Natera (MEX:NTRA) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,983.49, compared to a current price of MXN3,905.00 — trading 30.9% above its estimated fair value. The current ROE % is -19.54%. Natera's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Natera (MEX:NTRA), the current ROE % is -19.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natera (MEX:NTRA) Overvalued in 2026?
Based on GuruFocus' analysis, Natera stock appears to be overvalued.
The current stock price of MXN3,905.00 is trading 30.9% above its estimated GF Value™ of MXN2,983.49.
GuruFocus considers Natera to be Significantly Overvalued.
Key valuation signals for MEX:NTRA:
ROE %: -19.54%
GF Value™: MXN2,983.49 vs. price of MXN3,905.00 (30.9% above fair value)
No single metric tells the full story. See the MEX:NTRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
60GF Score
Get the complete analysis for MEX:NTRA
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NTRA has been successfully added to your 
